

Full Length Research Paper

Anti-diabetic effects of *Allium cepa* (onions) aqueous extracts on alloxan-induced diabetic *Rattus norvegicus*

Ozougwu, Jervas C.

Physiology and Biomedical Research Unit, Department of Zoology, University of Nigeria, Nsukka, Enugu State, Nigeria. E-mail: jervaschubby@yahoo.com. Tel: +2348034006816.

Accepted 3 September, 2010

The hypoglycaemic and hypolipidaemic effects of the increasing dosages of *Allium cepa* aqueous extracts on alloxan - induced diabetic *Rattus norvegicus* for possible use in the management of diabetes mellitus was investigated. Diabetes mellitus was induced in 54 out of a total of 63 adult *R. norvegicus* using 150 mg/kg of alloxan monohydrate. Increasing dosages (200, 250 and 300 mg/kg) of *A. cepa* aqueous extracts were given to the diabetic rats for six weeks while the control rats got either normal saline (1 ml) or increasing dosages of glibenclamide (2.5, 3.8 and 5.0 mg/kg) during the same period. Blood glucose level, total serum lipids and total serum cholesterol were assessed with routine methods. F-LSD was employed to test significant differences ($P < 0.05$) among treatment means. Increasing dosages of *A. cepa* aqueous extracts produced a dose-dependent significant ($P < 0.05$) reductions in the blood glucose levels, total serum lipid and total serum cholesterol when compared with that of the control rats. The most effective percentage reduction in blood glucose level, total serum lipids and cholesterol were observed at 300 mg/kg. From the experimental findings, it is possible to conclude that *A. cepa* studied exhibited promising hypoglycaemic and hypolipidaemic activity in alloxan-induced diabetic rats. It's hypoglycaemic and hypolipidaemic effects could represent a protective mechanism against the development of hyperglycaemia and hyperlipidaemia characteristic of diabetes mellitus.

Key words: *Allium cepa*, hypoglycaemia, hypolipidaemia, alloxan diabetic rats.

INTRODUCTION

The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia (high blood sugar) with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both (WHO, 1999). In 2006, according to the World Health Organization, at least 171 million people world wide suffer from diabetes (ADA, 2005). The incidence is increasing rapidly and it is estimated that by the year 2030, this number will double (ADA, 2005). Diabetes is a common and very prevalent disease affecting the citizens of both developed and developing countries (Erasto et al., 2005). The greatest increase in prevalence is however expected to occur in Asia and Africa, where more patients will likely be found by 2030. In 2007, there are about 23.6 million children and adults in the United States about 7.8% of the population suffering from diabetes. The national diabetes information clearing house estimates that the management of diabetes mellitus costs \$132 billion in the United States alone

every year. Statistical projections from India suggested that the number of diabetes will rise from 15 million in 1995 to 57 million in the year 2025, thus making India the country with the highest number of diabetics in the world (King et al., 1998; Boyle et al., 2001).

Allium cepa belongs to the family Liliaceae and is probably native of south west Asia and is widely cultivated throughout the world (Ikram, 1971). It has a globose bulb that is an underground part of the stem and is so often treated as a single household vegetable. *A. cepa* has been used medicinally for hundreds of years (Ikram, 1971). Its most popular modern uses is to lower blood pressure (Ikram, 1971), antiseptic (Jain, 1976), hypoglycaemic and hypocholesterlemic properties (Mathew and Augusti, 1975). The active ingredient in *A. cepa* is allyl propyl disulfide (APDS), though other active sulphurous compounds are present (Kumari et al., 1995). The use of herbal products for medicinal benefits has played an important role in nearly every culture on earth and for many years, the search for anti-diabetic products

will continue to focus on plants and other natural resources (Osinubi et al., 2006). The cost of administering modern antidiabetic drugs is beyond the reach of most people in the low income group and those living in the rural areas, hence the use of plants for the treatment of common diseases such as diabetes are very common. In line with the WHO (1980) expert committee on diabetes which recommends that traditional methods of management of diabetes should be further investigated. Also considering the economic resource constraints and cheapness of these herbal products, this present study was designed to determine the effects of increasing dosages of *A. cepa* (onions) on alloxan induced diabetic *Rattus norvegicus* and its possible mechanisms of action, for possible use in the control of hyperglycaemia and hyperlipidaemia characteristic of diabetes mellitus.

MATERIALS AND METHODS

Plant material

The *A. cepa* used for the experiment was bought from the Ogige Market, Nsukka, Nigeria. The plants were identified (Gbile, 1980) to species level at the Herbarium unit, Department of Botany, University of Nigeria, Nsukka where voucher specimen were kept.

Animal model

Sixty three (63) adult white wistar strain albino rats (*R. norvegicus*) weighing 200 to 250 g, bred in the animal house of the Faculty of Veterinary Medicine, University of Nigeria, Nsukka were used for the study. They were fed *ad libitum* with 30% crude protein (Guinea feed) commercial feed. They were allowed to acclimatize under standard photoperiodic condition in a clean rat cage in the Physiology Research Laboratory, Department of Zoology, University of Nigeria, Nsukka. All animals were maintained under the standard laboratory condition for temperature ($26 \pm 2^\circ\text{C}$) and light (12 h day length) and were allowed free access to food and water.

Preparation of plant extracts

The methods of Akah et al. (2004) and Habib et al. (2005) were used. Fresh health plant of *A. cepa* (2000 g) were washed, cut into small pieces and homogenized in a warring blender. The resulting mixture was soaked in 2 L of distilled water. The mixture was allowed to stand for 24 h with intermittent shaking. Following filtration, the filtrates were heated to dryness in a water bath and the weight of the crude extract determined. The extract was kept in refrigerator (4°C) thereafter. The extract was later reconstituted in normal saline (0.85% NaCl) at a concentration of 1 g/ml before administration.

Induction of diabetes mellitus

The methods of Osinubi et al. (2006) and Battu et al. (2007) were used to induce diabetes in the rats. 150 mg of alloxan per kg body weight of rat was administered intraperitoneally after overnight fast (access to only water) of twelve hours to make them more

susceptible to developing diabetes. Rats with serum glucose levels between (250 – 400 mg/dl) after two weeks were considered diabetic and used for the experiment.

Experimental design

The study was carried out on alloxan-induced diabetic rats for six weeks. The animals were fasted for sixteen hours before each experiment and blood sample collected from the eye of the rats. All parameters assessed were determined before the extract treatments of the animals (initials) and subsequently evaluated weekly for six weeks. The experimental design was the three by three Latin square design using 63 rats divided into two major groups:

Group I: Nine non diabetic rats (non diabetic control).
Group II: Fifty four alloxan induced diabetic rats.

Group I rats were divided into 3 subgroups (Ia, Ib, Ic) of 3 rats each in different cages and receives 1.0 ml of normal saline intraperitoneally daily.

Group II (fifty - four alloxan induced diabetic rats) were divided into 2 subgroups (IIa, IIb). Subgroups IIa, (twenty seven rats) were divided into 3 replicates (IIa₁, IIa₂, IIa₃) each replicate had three rats and received 200, 250 or 300 mg/kg of *A. cepa* aqueous extracts intraperitoneally daily, respectively.

The subgroups IIb was the diabetic control (twenty- seven rats) and were divided into 3 replicates (IIb₁, IIb₂ and IIb₃) each replicate had three rats and were administered 2.5, 3.8 and 5.0 mg/kg of standard antidiabetic drug (glibenclamide) daily for six weeks.

Blood glucose level determination

The glucose in a protein-free supernatant prepared from whole blood, serum or plasma was heated with a solution of a primary aromatic amine, O- toluidine, in glacial acetic acid. A green colour produced, probably a glycosylamine, the absorbance of which was measured using a spectrophotometer at 630 nm wavelength (Sood, 1999).

Determinations of total serum cholesterol

The cholesterol of the serum was oxidised to a tetraene derivative by ferric ions derived from ferric perchlorate using four test tubes marked test, control, standard and blank. The absorbance was measured using spectrophotometer at 590 nm wavelength and compared with that of a pure solution of cholesterol (Sood, 1999).

Determination of total lipids in serum

Serum 0.05 ml, was pipetted into a test tube (15 ml), containing 2.00 ml of concentration sulfuric acid ($d = 1.84$). The tube was swirled carefully, closed with a glass ball and placed in a bath of boiling water for 10 min. After cooling in cold water, 0.1 ml was transferred into another test tube (15 ml), containing 2.5 ml of phosphoric acid- vanillin reagent acid the solution was mixed carefully. The intensity of the pink colour that develops reaches its maximum after 30 min; it begins to fade after about 50 min. The absorbance of the sample was measured at 546 nm against the blank. The amount of lipid was read off an analytical care, which is obtained by analyzing four different amounts of total lipid of serum. Instead of total lipids, triolein was used as reference material. In this case, the values must be multiplied by a factor of 0.76. A standard




Figure 1. Effects of *A. cepa* on blood glucose levels of alloxan-induced diabetic rats. Values given represent the Mean \pm SD of 9 observations. NS = Normal saline represents non diabetic control, AC = *Allium cepa* and GL = glibenclamide represents diabetic control. $P < 0.05$, FLSD = 15.317.

solution of triolein (10 g/L) was used (Sood, 1999).

Data analysis

The data collected were pooled and analyzed for their central tendencies using descriptive statistic, values were expressed as mean \pm standard deviation of the observations. F-LSD was employed to test the significant differences ($P < 0.05$) among treatment means. All analyses were performed using Genstat (2007) for windows.

RESULTS

Blood glucose levels

The increasing dosage (200, 250 and 300 mg/kg) of *A. cepa* aqueous extracts produced dose- dependent significant ($P < 0.05$) reductions in the blood glucose levels of diabetic rats after 6 weeks of treatment when compared with that of the control rats (Figure 1). *A. cepa* at 200 mg/kg reduced fasting blood glucose levels by 62.9% (292.3 \pm 29.0 to 108.2 \pm 4.6), at 250 mg/kg it reduced fasting blood glucose levels by 69.7% (296.3 \pm 37.8 to 89.8 \pm 4.3) whereas at 300 mg/kg it reduced it by 75.4% (297.8 \pm 37.5 to 73.4 \pm 3.0). Glibenclamide at 2.5 mg/kg reduce fasting blood glucose levels by 76.4% (313.0 \pm 40.3 to 73.8 \pm 4.6), at 3.8 mg/kg it reduced it by 80.1% (319.4 \pm 54.0 to 63.6 \pm 2.2) while at 5.0 mg/kg it reduced it by 81% (310.7 \pm 35.0 to 59.0 \pm 1.6). The most effective percentage reduction in blood glucose level was observed at 300 mg/kg. Normal saline at 1 ml/kg had no effect on fasting blood glucose level.

Total serum lipids

The increasing dosage (200, 250 and 300 mg/kg) of *A. cepa* aqueous extracts produced a dose- dependent, significant ($P < 0.05$) reductions in the total serum lipids of diabetic rats after 6 weeks of treatment when compared with that of the control rats (Figure 2). *A. cepa* at 200 mg/kg reduced total serum lipids by 27.7% (184.0 \pm 9.9 to 133.1 \pm 5.8), at 250 mg/kg it reduced it by 29.4% (183.0 \pm 7.9 to 129.7 \pm 5.7) whereas at 300 mg/kg it reduced it by 44.4% (184.3 \pm 8.4 to 129.7 \pm 5.7). Glibenclamide at 2.5 mg/kg reduce total serum lipids by 22.9% (183.7 \pm 7.4 to 141.6 \pm 4.9), at 3.8 mg/kg it reduced it by 27.1% (183.3 \pm 7.7 to 133.7 \pm 3.7) while at 5.0 mg/kg it reduced it by 33.1% (182.9 \pm 8.3 to 122.4 \pm 4.4). The most effective percentage reduction in total serum lipids was observed at 300 mg/kg. Normal saline at 1 ml/kg had no effect on total serum lipids.

Total serum cholesterol

The increasing dosage (200, 250 and 300 mg/kg) of *A. cepa* aqueous extracts produced dose-dependent significant ($P < 0.05$) reductions in the total serum cholesterol of diabetic rats after 6 weeks of treatment when compared with that of the control rats (Figure 3). *A. cepa* at 200 mg/kg reduced total serum cholesterol by 20.4% (127.0 \pm 6.7 to 101.2 \pm 3.3), at 250 mg/kg it reduced it by 21.9% (131.0 \pm 4.4 to 102.2 \pm 2.3) while at 300 mg/kg it reduced it by 27.5% (130.1 \pm 3.7 to 94.7 \pm 4.2). Glibenclamide at 2.5 mg/kg reduced total serum




Figure 2. Effects of *A. cepa* on total serum lipids of alloxan induced diabetic rats. Values given represent the Mean \pm SD of 9 observations. NS = Normal saline represents non diabetic control, AC = *Allium cepa* and GL = glibenclamide represents diabetic control. $P < 0.05$, FLSD = 4.428.




Figure 3. Effects of *A. cepa* on total serum cholesterol of alloxan diabetic rats. Values given represent the Mean \pm SD of 9 observations. NS = Normal saline represents non diabetic control, AC = *Allium cepa* and GL = glibenclamide represents diabetic control. $P < 0.05$, FLSD = 3.67.

cholesterol by 22.9% (129.4 \pm 4.4 to 99.7 \pm 3.2), at 3.8 mg/kg it reduced it by 29.5% (129.1 \pm 4.3 to 91.0 \pm 3.7) while at 5.0 mg/kg it reduced it by 32.9% (129.4 \pm 3.7 to

86.8 \pm 3.1) after 6 weeks of treatment. The most effective percentage reduction in total serum cholesterol was observed at 300 mg/kg. Normal saline at 1 ml/kg had no

effects on total serum cholesterol.

DISCUSSION

Hypoglycaemic effects

Diabetes mellitus is probably the fastest growing metabolic disease in the world and as knowledge of the multifactorial /heterogeneous nature of the disease increases so does the need for more challenging and appropriate therapies (Ugochukwu et al., 2003). Traditional plant remedies have been used for centuries in the treatment of diabetes (Akhtar and Ali, 1984), but only a few have been scientifically evaluated. Alloxan is known for its selective pancreatic islet β – cell cytotoxicity and has been extensively used to induce diabetes mellitus in animals (Zarrow et al., 1964; Nafisa et al., 2007). Generalised increase in the level of blood glucose during diabetes have been consistently reported both in animal models (Mathew and Augusti, 1975; Hamme et al., 1991; Sharpe et al., 1998; Tukuncu et al., 1998) and humans especially those suffering from insulin dependent diabetes mellitus (Bell et al., 1984). In this study, increase in blood glucose level was observed on induction of diabetes mellitus in the rats models, which was reduced in a dose dependent manner with the highest percentage reduction at 300 mg/kg (Figure 1).

This is in line with the result of previous workers (Kumari et al., 1995; Sharma et al., 1997; Babu and Srivivasan, 1997). The active ingredient allyl propyl disulfide in onions may have antidiabetic properties as reported by previous studies (Andallu et al., 2001). It is also expected that onions extracts like glibenclamide may induce hypoglycaemia by stimulating insulin release and action, thereby enhancing cellular uptake and utilization of glucose in rats. It remains unclear whether the cellular glucose uptake may be due to increased insulin secretion or decreased insulin degradation rate. It is possible that onions extracts may act by undetermined ways apart from stimulating insulin production from the pancreatic islets since these would have been severely damaged by alloxan. The mechanism of the hypoglycaemic effects of onions extracts remains speculative, therefore further studies are required to unravel the pathway of its hypoglycaemic action and to shed more light on the hypoglycaemic constituents of the plants. It is however evident from this research that onions extracts studied contains hypoglycaemic agents capable of lowering blood glucose level in alloxan diabetic rats.

Hypolipidaemic effects

The prevalence of atherosclerosis and hyperlipidaemia among diabetics is on the increase worldwide. Alteration in serum lipids profile are known in diabetes, which are likely to increase the risk of coronary heart disease

(Laakso, 1996; Steiner, 1999; Massing et al., 2001). Hypercholesterolemia has been reported to occur in alloxan diabetic rats (Sharma et al., 1996; Pushparaj et al., 2000). Lipid profile which is altered in serum of diabetic patients (Orchard, 1990; Betteridge, 1994) appeared to be a significant factor in the development of premature atherosclerosis through increase in serum triglyceride and total cholesterol levels. The significant reduction in serum cholesterol and total lipids in a dose dependent manner as observed in this experiment were in agreement with previous reports (Blumenthal, 1998). The marked hyperlipidaemia that characterizes the diabetic state may be regarded as a consequence of the uninhibited actions of lipolytic hormones on the fat depots (Hardman and Limberd, 2001). The hypolipidaemic effect of onions may be connected to its active ingredient allyl propyl disulfide. A reduction in lipid profile could be beneficial in preventing diabetic complications as well as improving lipid metabolism in diabetics (Cho et al., 2002). Considering onions extracts effects on lipid components, it can be assumed a potential hypolipidaemic agent which will be a great advantage both in diabetic conditions as well as the associated atherosclerosis or hyperlipidaemic conditions.

Conclusions

It can be concluded from this study that the levels of total serum cholesterol, total serum lipids and blood glucose levels which were actually raised in alloxan diabetic rats can be lowered by onions aqueous extracts. The hypoglycaemic and hypolipidaemic effects are thus protective mechanisms against the development of atherosclerosis, hyperlipidaemia and hyperglycaemia common in diabetes mellitus. This may provide a basis for dietary supplementation of onions compounds in diabetics to reduce over dependence on drug.

REFERENCES

- Akah P, Njoku O, Nwanguma A, Akunyili D (2004). Effects of aqueous leaf extracts of *Vernonia amygdolina* on blood glucose and triglyceride levels of alloxan – induced diabetic rats. *Anim. Res. Int.*, 1(2): 90–94.
- Akhtar FM, Ali MR (1984). Study of the antidiabetic effect of a compound medicinal plant prescription in normal and diabetic rabbit. *J. Pak. Med. Assoc.*, 34: 239–244.
- ADA (2005). Total prevalence of diabetes and pre-diabetes. 15 pp. American Diabetes Association, (<http://www.diabetes.org/diabetes-statistics/prevalence.jsp>). Retrieved on 07/06/2007.
- Andallu B, Suryakantham V, lakshmi SB (2001). Effect of mulberry (*Morus indica* L) therapy on plasma and erythrocyte membrane lipids in patients with Type 2 diabetes. *Clin. Chem. Acta*, 314: 47–53.
- Babu PS, Srivivasan K (1997). Influence of dietary capsaicin and *Allium cepa* on the metabolic abnormalities associated with streptozocin induced diabetes mellitus. *Mole. Cell. Biochem.*, 125: 49–57.
- Battu GR, Mamidipalli, SN, Parimi R, Viriyala RK, Patchula RP, Mood LR (2007). Hypoglycaemic and antihyperglycemic effect of alcoholic extract of *Benincasa hispida* in normal and in alloxan induced

- diabetic rats. *Pharmacogn. Mag*, 3: 101-105.
- Bell BM, Hayes JR, Stout RW (1984). Lipoprotein, insulin and glycaemic control in diabetes. *Hormonal Metab. Res.*, 16: 252-260.
- Betteridge DJ (1994). Diabetic dyslipidaemia, *Am. J. Med.*, 96: 25-31.
- Blumenthal M (1998). The complete German commission E monographs: Therapeutic guide to herbal medicines. Am. Botanical Assoc., Austin, USA.
- Boyle JP, Honeycutt AA, Narayam KM, Hoerger TJ, Geiss LS, Chens H, Thompson TJ (2001). Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the United States. *Diabet. Care*, 24: 1936-1940.
- Cho SK, Park JY, Park EM, Choi MS, Lee MY, Jeon SM, Jang MK, Kim MJ, Park YB (2002). Alteration of hepatic antioxidant enzyme activities and lipid profile in streptozotocin – induced diabetic rats by supplementation of dandelion water extracts. *Clinical Chem. Acta*, 317: 109-117.
- Erasto P, Adebola PO, Grierson DS, Afolayan AJ (2005). An ethanobotanical study of plants used for the treatment of diabetes in the Eastern Cape Province, South Africa. *Afr. J. Biotechnol.*, 4(2): 1458-1460.
- Gbile ZO (1980). Vernacular Names of Nigerian Plants (Yoruba). Forestry Res. Institute Nig., Ibadan.
- Genstat for Windows Discovery Edition 2 (2007). Lawes Agricultural Trust, Rothamsted, United Kingdom.
- Habib MY, Islam MS, Awal MA, Khan MA (2005). Herbal products: A novel approach for diabetic patients. *Pak. J. Nutr.*, 4(1): 17-21.
- Hamme HR, Martins S, Federlin K, Geisen K, Brown M (1991). Aminoguanidine treatment inhibits the development of experimental diabetes retinopathy. *Proc. Natl. Acad. Sci.*, 88: 11555-11558.
- Hardman JG, Limberd LE (2001). Insulin, oral hypoglycaemic agents and the pharmacology of the endocrine pancreas, Pages 1383 - 1399. *In: Goodman and Gilman's. The Pharmacological Basis of Therapeutics (10th edition)*. McGraw Hill Company limited, U.S.A.
- Ikram MA (1971). A review on chemical and medicinal aspects of *Allium cepa*. *Pak. J. Sci. Ind. Res.*, 14(5): 395-398.
- Jain RC (1976). Onion and garlic in experimental cholesterol induced atherosclerosis in rabbit I. *Indian J. Med. Res.*, 64(10): 1509-1515.
- King H, Aubert RE, Herman WH (1998). Global burden of diabetes 1995 – 2005: Prevalence, numerical estimates and projections. *Diabetes Care*, 21: 1414-1431.
- Kumari K, Mathew BC, Augusti KT (1995). Anti-diabetic and hypolipidaemic effects of S – methyl cysteine sulfoxide isolated from *Allium cepa Linn*. *Indian J. Biochem. Biophys.*, 32: 49-54.
- Laakso M (1996). Lipids and lipoproteins as risk factors for coronary heart disease in non insulin dependent diabetes mellitus. *Ann. Med.*, 28: 341-345.
- Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ (2001). Lipid management among coronary artery disease patients in diabetes mellitus or advanced age. *Am. J. Cardiol.*, 87: 646-664.
- Mathew PT, Augusti KT (1975). Hypoglycaemic effects of onion, *Allium cepa linn* on diabetes mellitus. A preliminary report. *Indian J. Physiol. Pharmacol.*, 19(4): 212-217.
- Nafisa PC, Chakradhar VL, Vandana SP, Suresh RN (2007). An experimental evaluation of the antidiabetic and antilipidaemic properties of a standardized *Momordica charantia* fruit extract. *BMC Complementary Altern. Med.*, 7: 29-55.
- Orchard TJ (1990). Dyslipoproteinemia and diabetes: *Endocrinol. Metab. Clin. North Am.*, 19: 361-379.
- Osinubi AA, Ajayi OG, Adesiyun AE (2006). Evaluation of the anti-diabetic effect of aqueous leaf extracts of *Tripinanthus butungil* in male sprague Dawley rats. *Med. J. Islamic World Academy of Sci.*, 16(1): 41-47.
- Pushparaj P, Tan CH, Tan BK (2000). Effect of *Averrhoa bilimbi* leaf extract on blood glucose and lipids in streptozotocin diabetic rats. *J. Ethnopharmacol.*, 72: 69-76.
- Sharma SR, Dwivedi SK, Swarup D (1996). Hypoglycaemic and hypolipidaemic effects of *Cinnamon tomala nees* leaves. *Indian J. Exp. Biol.*, 34: 372-374.
- Sharma SS, Kochupilla IV, Gupta SK (1997). Antiemetic efficacy of ginger (*Zingiber officinale*) against cisplatin - induced emesis in Dogs. *J. Ethnopharmacol.*, 57: 93-96.
- Sharpe PC, Yue KM, Catterwood MA, Mcmarter D, Tribble ER (1998). The effects of glucose induced oxidative stress on growth and extracellular matrix gene expression of vascular smooth muscle cells. *Diabetologia*, 41: 1210-1219.
- Sood R (1999). *Medical Laboratory Technology Methods and Interpretations*. 5th edition, Jaypee Brothers Medical publishers Limited, New Delhi, India.
- Steiner G (1999). Risk factors for macrovascular disease in Type 2 diabetes. *Classic lipid abnormalities*. *Diabetes Care*, 22(3): 6-9.
- Tukuncu NB, Bcyraktar M, Varli K (1998). Reversal of defective nerve conductions with vitamin E supplementation in type 2 diabetes. *Diabetes Care*, 21: 1915-1918.
- WHO (1999). Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization Department of Noncommunicable Disease Surveillance. (<http://whglbdoc.who.int/hg/1999/WHO-NCD-NCS-99.2.pdf>). 60 p. Retrieved on 7/6/2007.
- WHO (1980). The World Health organization Committee on diabetes mellitus: Second Report. Technical Report Series 646. World Health Organization, Geneva.
- Zarrow MX, Yochim JM, McCarthy JL (1964). *Experimental Endocrinology, A Source Book of Basic Techniques*. Academic Press. New York.